Abstract
Introduction
Blood transfusion is the process of transferring blood or blood based products from donor into the circulatory system of recipient. 1 Transfusion of blood & blood component as a specialized modality of patient management saves million of lives each year worldwide. 2 The microbial agents are transmissible by blood transfusion & can cause morbidity & mortality in recipients. The infectious agents may present in the blood for long periods, sometimes in high titers, stability in blood stored at 4ºC or lower, long incubation period before the appearance of clinical signs, asymptomatic phase or only mild symptoms in the blood donor, hence not identifiable during the blood donor selection process. 3 In developing countries, blood safety remains an issue of major concern. Preventing the transmission of HBV through blood transfusion in developing countries are difficult. The priority objective of blood transfusion service is to ensure safety, adequacy, accessibility & efficiency of blood supply at all levels. These strategies have been extremely effective but transmission of HBV still occurs. Inability of the test to detect the disease in the pre-seroconversion or window phase of their infection, immunologically variant viruses, nonseroconverting chronic or immunosilent carriers & laboratory testing errors may be the possible causes. 4 Bangladesh, a developing country of South-East Asia, has a population of 160 million. HBV is the most common cause of chronic liver diseases including cirrhosis of liver, hepatic failure, & hepatocellular carcinoma. The risk of acquiring new HBV infection has been reduced in Bangladesh with the introduction of hepatitis B surface antigen (HBsAg) screening in blood donors. However, with the advent of 'occult HBV infection', it is now clear that many HBV-infected subjects may not express HBsAg (surface antigen to HBV) but may harbor HBV DNA. 5 From different studies of blood & organ recipients have recently shown HBV transmission from anti-HBc positive (core antibody against the core antigen), HBsAg negative donors, even when HBV DNA was undetectable in the donor. 6 In fact, the blood transfusion system of Bangladesh has not been optimized to tackle these situations. 5 
Hepatitis B Virus (HBV)
Hepatitis B virus (HBV) is an enveloped DNA virus that infects the liver and causes hepatocellular necrosis and inflammation. HBV infection can be either acute or chronic, and may range from asymptomatic infection or mild disease to severe or rarely fulminant hepatitis. 7 Epidemiology & Burden of HBV Around 2 billion people have evidence of past or present infection with HBV, & 240 million are chronic carriers of HBV surface antigen (HBsAg). Worldwide, it is estimated that around 650 000 people die each year from the complications of chronic hepatitis B virus infection. 7
Hepatitis B Virus (HBV) Infection
New-onset hepatitis B infection that may or may not be icteric or symptomatic. 7 For good understanding of HBV infection should know about some important conditions (Fig 1) 7, 8, 9, 10 determining the risk of chronic infection (Figure 3.1) . Chronicity is common following acute infection in neonates (90% of neonates born to hepatitis B e antigen [HBeAg]-positive mothers) & in young children under the age of 5 years (20-60%), but occurs rarely (<5%) when infection is acquired in adulthood. Worldwide, the majority of persons with CHB were infected at birth or in early childhood. 7, 8, 9, 10 Incubation Period:
The time between exposure of HBV and appearance of symptoms. 7, 8, 9, 10 Window Period: The time interval between the disappearance of HBsAg and the appearance of anti-HBS (antibody to surface antigen). 7, 8, 9, 10 Occult Hepatitis B Virus (HBV) Infection: Absence of HBsAg despite presence of anti-HBc (core antibody) and HBV-DNA <1000 copies/ml or <200 IU/ ml (Fig 2) 
Natural Immunity
Recovery is accompanied by clearance of HBsAg with seroconversion to anti-HBs (antibodies to hepatitis B surface antigen) usually within 6 months. 7, 8, 9, 10 Chronic Hepatitis B Virus (HBV) Infection Persistence of hepatitis B surface antigen (HBsAg) for six months or more along with anti-HBcIgG (IgG antibodies to hepatitis B core antigen) after acute infection indicate chronicity. Age is a key factor in Transmission of HBV through transfusion HBV is spread predominantly by percutaneous or mucosal exposure to infected blood. 7 Several studies from different countries including Bangladesh indicates that, blood transfusion is the main source for transmission of HBV (Table I & II) . A study from West Bengal, India, a neighboring Indian province of Bangladesh has reported that 21.3% HBsAg negative & anti-HBc-positive blood donors were harboring HBV DNA in their blood. 44 Another study from India also showed that 7.5% of HBsAg-negative, anti-HBc positive blood was expressing HBV DNA. Surprisingly, 4.6% people expressing both anti-HBc & anti-HBs were also expressing HBV DNA in their blood. 45 Presence of HBV DNA in HBsAg-negative blood donors has also been reported from other Asian countries, such as Iran that showed HBV DNA among 12.2% HBsAg-negative, anti-HBc positive donors. 46 Studies In this dangerous situation, almost nothing is known about the real extent of problem with anti-HBc positivity in this country. Recently, nucleic acid testing (NAT) has been adopted by many countries to avoid transfusion-induced hepatitis. 52 Also, we would not advocate for immediate starting of NAT for donor screening in Bangladesh, as this is neither feasible nor acceptable in the context of present socioeconomic condition of this country. It is usually discussed that NAT establishment is a costly endeavor in Bangladesh & other developing countries. 5
Tests methods
According to WHO & National guideline, the main types of assay used for blood screening of HBV are: 32
• Immunoassays (lAs):
• Enzyme immunoassays (EIAs)
• Chemiluminescent immunoassays (CLIAs)
• Rapid/simple single use assays (rapid tests)
• Nucleic acid amplification technology (NAT) assays.
Universal Choice
The blood transfusion department of medical colleges, institutes & specialized hospitals should perform EIAs & CLIAs for blood screening in addition to the current system of rapid testing. 32
In Special Situation
Only rapid tests may be considered in case emergency screening (when blood is needed urgently) or in remote areas with low workloads or limited number of tests are performed daily & limited facilities, when equipment is lacking or where there may be no electricity e.g. district blood centers & Upazila health complexes. 32 • Regarding HBV, Core antibody (anti-HBc) should include in national donor screening program.
Why EIAs & CLIAs Rather than Strip
• In future, nucleic acid testing (NAT) for HBV should be included for safe blood transfusion in Bangladesh.
Future Prospect
Establishment of a nationally coordinated blood transfusion service, collection of blood only from voluntary donors, testing of all blood for compatibility & transfusion transmissible infections (TTIs) with appropriate method of testing & reduction of unnecessary transfusion will be the key factors for excellent blood transfusion service (BTS) in future. It is widely expected that BTS will be able to supply HBV free blood from voluntary blood donors to all parts of the country in timely manner with sufficient quantity.
